Clinical Trials in Modena, Emilia-Romagna

9 recruiting

Showing 19 of 9 trials

Recruiting
Phase 4

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

Breast Cancer
Hoffmann-La Roche320 enrolled28 locationsNCT06274515
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer
Hoffmann-La Roche450 enrolled226 locationsNCT06790693
Recruiting
Phase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

ObesityKnee osteoarthritis (OA)
Novo Nordisk A/S400 enrolled82 locationsNCT07481630
Recruiting
Phase 2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc310 enrolled91 locationsNCT05128825
Recruiting

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Lung Cancer, Hepatocellular Carcinoma
Hoffmann-La Roche700 enrolled88 locationsNCT07284121
Recruiting
Phase 3

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease
Hoffmann-La Roche800 enrolled146 locationsNCT07170150
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled217 locationsNCT06793215
Recruiting
Phase 3

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting

Prevention ICONA Dedicated Ensemble

HIV-1-infectionHIVPrEP+3 more
Fondazione ICONA5,000 enrolled53 locationsNCT07186244